Donor cell-derived hematologic neoplasm (DDHN) is defined as a de novo hematologic malignancy originated from transplanted donor stem cells, distinct from the original recipient's disease (ORD). Its prevalence and biological mechanisms remain poorly defined. We conducted a nationwide study to estimate the prevalence of...
Maria Gabarrós-Subirà, H. Pomares, F. Beas et al.· Blood· 0 citations
RAS mutations are recurrent in acute myeloid leukemia (AML); yet, their genomic and clinical landscape remain poorly characterized. We analyzed centralized molecular profiling data in 8,553 patients with newly diagnosed AML. Of these, 1,775 (21%) harbored RAS mutations: NRAS in 1,103 (13%), KRAS in 445 (5%), and both i...
E. Rodríguez-Arbolí, E. Soria-Saldise, E. Barragán et al.· Blood· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.